When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
PHAT - Phantom Pharmaceuticals Could See Substantial Upside With 2 Upcoming Phase 3 Readouts
Phathom Pharmaceuticals Inc.
Phantom Pharmaceuticals is developing a next-generation stomach acid reducer that would represent the first new mechanism of action in the space in 30 years.
Phantom's drug, vonoprazan, has already succeeded in multiple Phase 3 trials overseas, which should bode well for its two ongoing US Phase 3 trials.
Phantom's $1.2 billion market cap will likely prove very cheap if vonoprazan gets approved, given the extremely large market for branded reflux medications.